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Lipid Profile Changes after Switch to Atazanavir from 
other Protease Inhibitor-based Combined Antiretroviral 
Treatment in HIV-infected Korean
Dyslipidemia, one of the major disadvantages of use of protease inhibitor (PI), is a 
risk factor for cardiovascular disease in HIV-infected patients receiving antiretroviral 
treatment. Little is known about the effect of a switch from another PI to unboosted 
atazanavir (ATV) on the lipid profile. The aim of this study was to evaluate changes in 
the lipid profile after switching from another PI to either unboosted or boosted ATV 
in HIV-infected Koreans. We retrospectively collected data on the serum lipid profile 
at the time of the switch (week 0), and weeks 12 and 24 after the switch, as well as 
clinical characteristics at week 0 in a total of 27 patients. Triglyceride (TG) showed a 
significant decrease at weeks 12 and 24 in all patients (196 vs. 174 mg/dL, P=0.048 
and 196 vs. 150 mg/dL, P=0.021, respectively). However, these effects were only 
observed in the unboosted ATV group (N=14; 239 vs. 125 mg/dL, P=0.017 and 239 
vs. 87 mg/dL, P=0.021, respectively). For total cholesterol, only the unboosted ATV 
group at 24 weeks showed a significant decrease (184 vs. 158 mg/dL, P=0.031). No 
significant changes were observed in LDL- and HDL-cholesterol at weeks 12 and 24 
in both the unboosted and boosted ATV groups. These results suggest that changing 
to unboosted ATV from another PI may ameliorate high TG and total cholesterol in 
HIV-infected Koreans. 
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The introduction of ritonavir (RTV)-boosted protease inhibitor (PI) 
has contributed significantly to successful implementation of combined 
antiretroviral treatment (cART), resulting in a significant reduction in morbidity 
and mortality associated with AIDS-defining illnesses [1]. As the lifespan of 
HIV-infected individuals grows longer, the metabolic complications in chronic 
asymptomatic HIV-infected individuals are becoming a more important 
problem [2, 3].   
Metabolic abnormality, especially dyslipidemia, is one of the major 
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disadvantages of boosted PI-containing cART; therefore, the risk 
for CVD must be closely monitored in patients receiving boosted 
PI [4]. 
Since approval of atazanavir (ATV) as the first PI for once-
daily dosing by the U.S. FDA [5], large numbers of randomized 
controlled trials have demonstrated that ATV is comparable in 
efficacy to other established PIs [6, 7], and that ATV has fewer 
effects on metabolic abnormalities [8], suggesting a strategy for 
avoidance of the primary side effect of PI. As a result, boosted 
ATV (ATV/r) is recommended as one of the preferred PI drugs [9, 
10]
Unboosted ATV has shown similar efficacy and safety, 
compared with ATV/r, both when used as a component of the 
initial regimen and when used for maintenance after initial 
suppression with another boosted PI [11]. Significantly favorable 
results for lipid profile were observed for the unboosted ATV, 
confirming its lower metabolic side effects [12]. However, 
because these studies were conducted mainly in Western 
countries [12], the effect of ATV on lipid profile in HIV-infected 
East Asians has not been clarified. Therefore, we conducted 
this study in order to investigate the impact of ATV according 
to RTV co-administration on changes in lipid profile after 
switching from other PI in HIV-infected Koreans. Identification 
of HIV-infected Koreans who received switching therapy from 
another PI to unboosted or boosted ATV with maintenance of 
the same nucleoside-analogue reverse transcriptase inhibitors 
between December 2005 and December 2009 was based on 
a retrospective review of the electronic database at Severance 
Hospital. Subjects with good adherence assessed through clinic 
visits and lipid testing with regular three-month intervals during a 
period of more than a six months after the switch were included. 
We excluded patients who had previously taken lipid-lowering 
agents or other drugs that can cause a change in lipid level. In 
addition, patients with opportunistic infection or malignancy 
while undergoing current treatment or underlying condition 
of chronic renal or liver disease according to the International 
Classification of Disease, 10th Revision [13] were excluded from 
the study. The switching therapy was determined by each HIV-
special physician. As it presented no risk to prejudice subject 
rights and welfare, the Institutional Review Board approved the 
design of the study. 
Data on demographic characteristics, PI used before the switch, 
and results of blood tests, including CD4+ cell counts, plasma HIV-
RNA viral load (VL), and lipid level were retrospectively collected. 
The Friedewald formula was used for calculation of Low-density 
lipoprotein (LDL)-cholesterol [14], except in patients with 
triglyceride (TG) higher than 400 mg/dL. 
Subjects were divided into two groups based on whether 
or not RTV was taken simultaneously with ATV. The baseline 
characteristics at the time of the switch (week 0) were compared 
between the groups. In addition, the lipid profile of total 
cholesterol, TG, high-density lipoprotein (HDL)-cholesterol, 
LDL-cholesterol, and total/HDL-cholesterol ratio at 0, 12, and 24 
weeks after the switch were compared in each group. 
Because all continuous variables showed skewed distribution, 
these data were expressed as median and interquartile range 
(IQR). The Mann-Whitney U and Fisher’s exact test were used 
in comparisons between unboosted and boosted ATV groups. 
Wilcoxon signed-rank tests were used for identification of the 
change in lipid profile from week 0 in each group. SPSS software 
for Windows, version 18.0 (SPSS, Chicago, IL, USA) was used in 
performance of all statistical tests. P-value≤0.05 was considered 
statistically significant.
Among a total of 27 participants, 14 were switched to un-
boosted ATV, while 13 were switched to ATV/r. The median age 
of total patients was 39 (25-46) years. The CD4+ T cell count and 
plasma HIV-RNA VL at week 0 were 430 (250-535) cells/mm3 
and 1.59 (1.27-4.17) log 10 copies/mL, respectively. The PI used 
before the switch was lopinavir/ritonavir (77.8%) or nelfinavir 
(22.2%). In comparison of the two groups according to RTV use 
at week 0, the age of subjects in the ATV/r group was higher than 
that of subjects in the unboosted ATV group (45 vs. 36 years, 
P=0.018). TG in the unboosted ATV group was higher than that 
of the ATV/r group (239 vs. 195 mg/dL, P=0.021) (Table 1). At 12 
and 24 weeks after the switch, plasma HIV-RNA VL was similar 
between the unboosted and boosted ATV group (1.27 vs. 2.17 log 
10 copies/mL, P=0.168 and 1.27 vs. 1.27 log 10 copies/mL, P=0.684, 
respectively). CD4+ T cell counts were significantly higher in the 
unboosted ATV group, compared with the boosted ATV group at 
12 weeks only (480 vs. 233 cells/mm3, P=0.031). 
At week 12, TG of all patients had decreased, from 196 to 
174 mg/dL (P=0.048). This decrease continued to week 24 (150 
mg/dL, P=0.021). TG of the unboosted ATV group decreased 
from 239 to 125 mg/dL (P=0.017) at week 12 and the continued 
decrease was observed (87 mg/dL, P<0.001) at week 24. In the 
ATV/r group, no significant change in TG was observed until 
week 24 (Table 2). TG was significantly lower in the unboosted 
ATV group, compared with the ATV/r group at both week 12 
(P=0.034) and at week 24 (P <0.001).
Total cholesterol in the unboosted ATV group showed a 
significant decrease, from 184 to 158 mg/dL at week 24 only 
(P=0.031). In the ATV/r group, no significant changes in total 
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cholesterol were observed at both week 12 and week 24. Among 
subsets of serum cholesterol, only total/HDL-cholesterol ratio 
showed a significant decrease in the unboosted ATV group at 
week 24 (4.8 at week 0 vs. 2.8 at week 24, P=0.007) (Table 2).
Results of this study revealed a favorable effect on lipid profile 
in HIV-infected Koreans who received switch therapy from 
another PI to unboosted ATV. However, this result was observed 
in TG and total cholesterol, but not in LDL- or HDL-cholesterol. 
In the lipid profile of all patients, a significantly continuous 
decrease was observed in TG only at week 12 and week 24. The 
decreasing trend of TG and total cholesterol was prominent in 
the unboosted ATV group, whereas the ATV/r group showed no 
Table 1. Baseline Characteristics and Demographics of All Study Participants at the Time of Switching to Unboosted or Boosted Atazanavir (0-week)
Total (N=27) Switch to ATV (N=14) Switch to ATV/r (N=13) P-value* 
Age, years 39 (25-46) 36 (23-42) 45 (34-49) 0.018a
Gender, male 26 (96.3) 13 (92.9) 13 (100.0) 1.000b
PI used before switch 1.000b
  Lopinavir/Ritonavir 21 (77.8) 11 (78.6) 10 (76.9)
  Nelfinavir 6 (22.2) 3 (21.4) 3 (23.1)
Plasma HIV-RNA VL, log10 copies/mL 1.59 (1.27-4.17) 1.43 (1.27-2.28) 2.27 (1.27-4.51) 0.298
a
CD4+ T cell counts, cells/mm3 430 (250-535) 492 (299-567) 303 (162-477) 0.094a
Lipid profile 
 Triglyceride, mg/dL 196 (150-288) 239 (154-298) 195 (113-294) 0.021
 Total cholesterol, mg/dL 173 (165-203) 184 (172-222) 167 (149-176) 0.391a
 LDL-cholesterol, mg/dL 94 (68-118) 116 (65-127) 90 (77-101) 0.112a
 HDL-cholesterol, mg/dL 47 (40-52) 48 (42-52) 42 (38-60) 0.386a
 Total/HDL-cholesterol ratio 4.5 (3.4-5.0) 4.8 (3.3-5.3) 4.2 (3.2-4.8) 0.211a
The data are presented as the median (interquartile ranges) or number (percent). *Comparisons between unboosted and boosted ATV groups. 
aMann-Whitney U test.
bFisher’s exact test. 
ATV, atazanavir; ATV/r, ritonavir-boosted atazanavir; PI, protease inhibitor; VL, viral load; LDL, low-density lipoprotein; HDL, high-density lipoprotein.
Table 2. Changes of Lipid Profile and CD4+ T Cell Count, Plasma HIV-RNA Viral Load at 0, 12, and 24-week after the Switch to Unboosted or Boosted Atazanavir 
Week
Total (N=27) Switch to ATV (N=14) Switch to ATV/r (N=13)
P-valuea P-valuea P-valuea
Triglyceride,mg/dL 0b 196 (150-288) 239 (154-298) 195 (113-294)
12 174 (100-280) 0.048 125 (76-277) 0.017 178 (152-327) 0.067
24 150 (87-241) 0.021 87 (74-157) <0.001 207 (136-280) 0.612
Total cholesterol,mg/dL 0b 173 (165-203) 184 (172-222) 167 (149-176)
12 171 (153-187) 0.357 172 (152-185) 0.198 170 (154-197) 0.236
24 162 (139-204) 0.271 158 (135-203) 0.031 165 (155-205) 0.689
LDL-cholesterol,mg/dL 0b 94 (68-118) 116 (66-127) 90 (77-101)
12 84 (69-106) 0.382 88 (57-106) 0.091 84 (69-107) 0.753
24 79 (71-120) 0.767 94 (62-130) 0.355 79 (73-100) 0.499
HDL-cholesterol,mg/dL 0b 47 (40-52) 48 (42-52) 42 (38-60)
12 42 (36-53) 0.575 48 (37-55) 0.865 39 (36-49) 0.463
24 48 (39-57) 0.282 49 (39-61) 0.180 48 (38-58) 0.610
Total/HDL-cholesterol ratio 0b 4.5 (3.4-5.0) 4.8 (3.3-5.3) 4.2 (3.2-4.8)
12 3.9 (3.1-4.8) 0.422 3.4 (3.0-4.5) 0.063 4.5 (3.9-4.9) 0.345
24 2.8 (2.6-4.8) 0.011 2.8 (2.6-5.3) 0.007 4.0 (2.6-4.4) 0.735
CD4+ T cell count, cells/mm3 0b 430 (250-535) 492 (299-567) 303 (162-477)
12 403 (254-577) 0.653 480 (348-607) 1.000 233 (150-386) 0.463
24 460 (270-545) 0.153 468 (341-518) 0.779 412 (245-556) 0.060
Plasma HIV-RNA VL, log10 copies/mL 0
b 1.59 (1.27-4.17) 1.43 (1.27-2.28) 2.27 (1.27-4.51)
12 1.38 (1.27-1.74) 0.028 1.27 (1.27-1.69) 0.128 2.17 (1.27-4.45) 0.225
24 1.27 (1.27-1.59) 0.050 1.27 (1.27-1.50) 0.465 1.27 (1.27-1.59) 0.063
The data are presented as the median (interquartile ranges). 
aWilcoxon signed-rank test. 
bReference values. 
ATV, atazanavir; ATV/r, ritonavir-boosted atazanavir; LDL, low-density lipoprotein; HDL, high-density lipoprotein; VL, viral load
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specific changes in lipid profile after switch of PI.
Triglyceride was the parameter that distinctly confirmed 
the favorable effect in the ATV-based regimen [15]. Similar to 
several studies conducted in Western countries [4], in our study, 
the decrease of TG was more prominent in the unboosted ATV 
group. The baseline TG before the switch in the unboosted ATV 
group was higher than that in the ATV/r group. In patients with 
higher TG, physicians may decide to change to an unboosted 
ATV because boosting can affect a significant elevation in TG [16]. 
At week 12, significant difference of TG was observed between 
the unboosted and boosted ATV group. At week 24, decrease 
of TG in the unboosted ATV group became prominent, which 
was caused by a sustained decrease in TG of the unboosted 
ATV group. There may be two potential causes to account for 
this favorable change of TG in the unboosted ATV group. First, 
it could be due to removal of an unfavorable effect of RTV on 
TG [16]. Due to a high percentage of RTV use in both groups 
(unboosted ATV: 77.8%, ATV/r: 76.9%), the shift to unboosted 
ATV may possibly have brought about removal of the unfavorable 
effect of RTV on TG. Second, it is possible that superiority of ATV 
regarding metabolic abnormalities, compared with other PI, 
could aid in improvement of TG. Several studies have confirmed 
a favorable effect on TG of switching from boosted PI to ATV/r [17, 
18]. 
Meanwhile, LDL- and HDL-cholesterol did not show improve-
ment after the switch in both the unboosted ATV and ATV/
r groups. This finding is in agreement with prior studies that 
compared ATV and ATV/r as a part of a maintenance regimen [11, 
19]. ATV/r showed no superiority compared with other PI in LDL- 
and HDL-cholesterol [7, 17, 18]. One study reported improvement 
of HDL-cholesterol after the switch from another PI to unboosted 
ATV; however, the sample included in the previous study was 
made up of HIV-infected patients with hyperlipidemia, therefore, 
it is difficult to compare this with results of our study [20].
Considering that, in most established studies, shifting from 
another PI to ATV resulted mainly in improvement of total 
cholesterol and non-HDL-cholesterol [20], a switch to ATV is not 
believed to have a direct effect on HDL-cholesterol. 
There are several limitations to this study. Because only 27 
patients were included, subanalysis to evaluate the cause of 
the results could not be performed. In addition, the baseline 
characteristics of both groups had some differences. The age 
of subjects in the unboosted ATV group was lower than that 
of subjects in the ATV/r group. Considering that older age 
is associated with metabolic syndrome, this difference may 
be a limitation of this study. Another difference was that the 
baseline TG of the unboosted ATV group was higher than 
that of the ATV/r group. However, because the results showed 
a continuous decrease of TG until week 24 after baseline 
difference disappeared at week 12 in the unboosted ATV group, 
this difference was thought not to influence the outcome of our 
study. 
In conclusion, results of our analysis may implicate that a switch 
to unboosted ATV from another PI is related to favorable changes 
in lipid profile, particularly TG, and that boosting removes the 
favorable effect of ATV on lipid profile in HIV-infected Koreans.
References
1.  Naggie S, Hicks C. Protease inhibitor-based antiretroviral 
therapy in treatment-naive HIV-1-infected patients: the evi-
dence behind the options. J Antimicrob Chemother 2010;65: 
1094-9. 
2.  Friis-Møller N, Weber R, Reiss P, Thiébaut R, Kirk O, d'Arminio 
Monforte A, Pradier C, Morfeldt L, Mateu S, Law M, El-Sadr W, 
De Wit S, Sabin CA, Phillips AN, Lundgren JD; DAD study 
group. Cardiovascular disease risk factors in HIV patients-
association with antiretroviral therapy. Results from the DAD 
study. AIDS 2003;17: 1179-93. 
3.  Barbaro G. Highly active antiretroviral therapy-associated 
metabolic syndrome: pathogenesis and cardiovascular risk. 
Am J Ther 2006;13:248-60. 
4.  Malan DR, Krantz E, David N, Wirtz V, Hammond J, McGrath 
D; 089 Study Group. Efficacy and safety of atazanavir, with or 
without ritonavir, as part of once-daily highly active anti-
retroviral therapy regimens in antiretroviral-naive patients. J 
Acquired Immune Defic Syn-dromes 2008;47:161-7. 
5.  Raja A, Lebbos J, Kirkpatrick P. Atazanavir sulphate. Nat Rev 
Drug Discov 2003;2:857-8. 
6.  Squires K, Lazzarin A, Gatell JM, Powderly WG, Pokrovskiy V, 
Delfraissy JF, Jemsek J, Rivero A, Rozenbaum W, Schrader S, 
Sension M, Vibhagool A, Thiry A, Giordano M. Comparison of 
once-daily atazanavir with efavirenz, each in combination 
with fixed-dose zidovudine and lamivudine, as initial therapy 
for patients infected with HIV. Acquired Immune Defic 
Syndromes 2004;36:1011-9. 
7.  Johnson M, Grinsztejn B, Rodriguez C, Coco J, DeJesus E, 
Lazzarin A, Lichtenstein K, Wirtz V, Rightmire A, Odeshoo L, 
McLaren C. 96-week comparison of once-daily atazanavir/
ritonavir and twice-daily lopinavir/ritonavir in patients with 
multiple virologic failures. AIDS 2006;20:711-8. 
8.  Gatell J, Salmon-Ceron D, Lazzarin A, Van Wijngaerden E, 
  http://dx.doi.org/10.3947/ic.2012.44.5.377 • Infect Chemother 2012;44(5):377-381      381www.icjournal.org
Antunes F, Leen C, Horban A, Wirtz V, Odeshoo L, Van den 
Dungen M, Gruber C, Ledesma E; SWAN Study Group. Efficacy 
and safety of atazanavir-based highly active antiretroviral 
therapy in patients with virologic suppression switched from a 
stable, boosted or unboosted protease inhibitor treatment 
regimen: the SWAN Study (AI424-097) 48-week results. Clin 
Infect Dis 2007;44:1484-92. 
9.  Panel on Antiretroviral Guidelines for Adults and Adolescents. 
Guidelines for the use of antiretroviral agents in HIV-1-infected 
adults and adolescents. Department of Health and Human 
Services. October 10, 2006. Available from: http://aidsinfo.nih.
gov/. Accessed 29 December 2011.
10.  Panel on Antiretroviral Guidelines for Adults and Adolescents. 
Guidelines for the use of antiretroviral agents in HIV-1-infected 
adults and adolescents. Department of Health and Human 
Services. October 14, 2011. Available from: http://www.
aidsinfo.nih.gov/. Accessed 29 December 2011.
11.  Squires KE, Young B, Dejesus E, Bellos N, Murphy D, Zhao HH, 
Patel LG, Ross LL, Wannamaker PG, Shaefer MS; ARIES study 
team. Similar efficacy and tolerability of atazanavir compared 
with atazanavir/ritonavir, each with abacavir/lamivudine 
after initial suppression with abacavir/lamivudine plus ritona-
virboosted atazanavir in HIV-infected patients. AIDS 2010;24: 
2019-27. 
12.  Ghosn J, Carosi G, Moreno S, Pokrovsky V, Lazzarin A, Pialoux 
G, Sanz-Moreno J, Balogh A, Vandeloise E, Biguenet S, Leleu G, 
Delfraissy JF. Unboosted atazanavir-based therapy maintains 
control of HIV type-1 replication as effectively as a ritonavir-
boosted regimen. Antivir Ther 2010;15:993-1002. 
13.  Han SH, Chin BS, Lee HS, Jeong SJ, Choi HK, Kim CO, Choi JY, 
Song YG, Lee HC, Kim JM. Serum retinol-binding protein 4 
correlates with obesity, insulin resistance, and dyslipidemia in 
HIV-infected subjects receiving highly active antiretroviral 
therapy. Metabolism  2009;58:1523-9. 
14.  Friedewald WT, Levy RI, Fredrickson DS. Estimation of the 
concentration of low-density lipoprotein cholesterol in plasma, 
without use of the preparative ultracentrifuge. Clin Chem 
1972;18:499-502. 
15.  Möbius U, Lubach-Ruitman M, Castro-Frenzel B, Stoll M, Esser 
S, Voigt E, Christensen S, Rump JA, Fätkenheuer G, Behrens 
GM, Schmidt RE. Switching to atazanavir improves metabolic 
disorders in antiretroviral-experienced patients with severe 
hyperlipidemia. J Acquired Immune Defic Syndr 2005;39:174-
80. 
16.  Shafran S, Mashinter L, Roberts S. The effect of low‐dose 
ritonavir monotherapy on fasting serum lipid concentrations. 
HIV Med 2005;6:421-5. 
17.  Mallolas J, Podzamczer D, Milinkovic A, Domingo P, Clotet B, 
Ribera E, Gutiérrez F, Knobel H, Cosin J, Ferrer E, Arranz JA, 
Roca V, Vidal F, Murillas J, Pich J, Pedrol E, Llibre JM, Dalmau 
D, García I, Aranda M, Cruceta A, Martínez E, Blanco JL, 
Lazzari E, Gatell JM; ATAZIP Study Group. Efficacy and safety 
of switching from boosted lopinavir to boosted atazanavir in 
patients with virological suppression receiving a LPV/ 
r-containing HAART: the ATAZIP study. J Acquired Immune 
Defic Syndr 2009;51:29-36. 
18.  Molina JM, Andrade-Villanueva J, Echevarria J, Chetchotisakd 
P, Corral J, David N, Moyle G, Mancini M, Percival L, Yang R, 
Wirtz V, Lataillade M, Absalon J, McGrath D; CASTLE Study 
Team. Once-daily atazanavir/ritonavir compared with twice-
daily lopinavir/ritonavir, each in combination with tenofovir 
and emtricitabine, for management of antiretroviral-naive 
HIV-1-infected patients: 96-week efficacy and safety results of 
the CASTLE study. J Acquired Immune Defic Syndr 2010;53: 
323-32. 
19.  Ghosn J, Carosi G, Moreno S, Pokrovsky V, Lazzarin A, Pialoux 
G, Sanz-Moreno J, Balogh A, Vandeloise E, Biguenet S, Leleu G, 
Delfraissy JF. Unboosted atazanavir-based therapy maintains 
control of HIV type-1 replication as effectively as a ritonavir-
boosted regimen. Antivir Ther 2010;15:993-1002. 
20.  Sension M, Andrade Neto JL, Grinsztejn B, Molina JM, Zavala I, 
González-García J, Donnelly A, Phiri P, Ledesma E, McGrath D; 
067 Study Group. Improvement in lipid profiles in antire-
troviral-experienced HIV-positive patients with hyperlipide-
mia after a switch to unboosted atazanavir. J Acquired Immune 
Defic Syndr 2009;51:153-62. 
